Global Chapare Hemorrhagic Fever (CHHF) Market, By Treatment (Intravenous Therapy, Pain Relievers, Transfusions, Management of hydration, Others), Transmission (Direct Contact, Indirect Contact), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, homecare, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Chapare Hemorrhagic Fever (CHHF) Market Analysis and Size
In 2020, because of the spread of COVID-19, the U.S. Centers for Disease Control and Prevention (CDC) started researching other deadly viruses, and discovered the chapare virus. The virus can be transmitted from human to human in direct contact with an infected rodent. It was first witnessed in Bolivia, where it initially resulted in a pandemic and later came under control in no time. Increase in the occurrence of infectious disease, rising healthcare expenditure boost the market growth.
Data Bridge Market Research analyses a growth rate in the chapare hemorrhagic fever (CHHF) market in the forecast period 2023-2030. The expected CAGR of chapare hemorrhagic fever (CHHF) market is tend to be around 4.50% in the mentioned forecast period. The market value is USD 1.54 billion in 2022, and it would grow upto USD 2.2 billion by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chapare Hemorrhagic Fever (CHHF) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Intravenous Therapy, Pain Relievers, Transfusions, Management of hydration, Others), Transmission (Direct Contact, Indirect Contact), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, homecare, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland.), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Amorphex Therapeutics Holdings, Inc (U.S.), Bausch Health Companies Inc. (Canada.), WEX Pharmaceuticals Inc (Canada), Zynerba Pharmaceuticals, Inc (U.S.), Estrellas Life Sciences Private Limited (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Chapare hemorrhagic fever (CHHF) is a type of viral infectious disease that is caused by chapare virus. It belongs to the Arenaviridae family. This is an animal borne virus and zoonotic. CHHF is an acute viral hemorrhagic fever which is typically characterised by arthralgia, myalgia, fever, abdominal pain, skin rashes, vomiting, bleeding gums and multiple hemorrhagic signs. It typically causes a hemorrhagic fever similar to Ebola along with pain behind the eyes.
Chapare Hemorrhagic Fever (CHHF) Market Dynamics
Drivers
- Increased cases of chapare hemorrhagic fever (CHHF)
The increasing cases of chapare hemorrhagic fever (CHHF) among diverse parts of the country are increasing market growth. Ebola virus has killed 12 of 23 infected people in Guinea in 2021 and six of 12 in the DR Congo. There have been several cases and outbreaks of Marburg virus disease, with Uganda reporting small outbreaks in 2012 and major outbreaks occurring in central and southern Africa. Therefore, it demands advanced treatment and boosts the growth of the market.
- Increase in elderly population
As per the research, the aging population is more susceptible to this disease. As per the Aging World reports from 2015, there were around 562 million people 65 and older globally, which increased the disease's occurrence and boosted the growth of the hemorrhagic fever treatment market.
Opportunities
- Growing acquisitions and collaborations
The growing acquisitions of diverse market players are creating much opportunities for the market growth. For instance, Teva Pharmaceuticals acquired Allergan’s generics business in August 2016. This acquisition has helped the company deliver the highest-quality generic medicines at the most reasonable prices, and unlocking value to patients, healthcare systems and investors globally.
Restraints/Challenges
- Lack of proper cure
The lack of treatments for chapare hemorrhagic fever (CHHF) is hindering the growth of the market. The treatment is expensive because of the lack of FDA-approved drugs, which leads to lower affordability. No appropriate treatment can cure chapare hemorrhagic fever (CHHF)s and immunizations exist for only two of the many chapare hemorrhagic fever (CHHF) deterring the market growth.
- Increased generic influx
The patent expiry of most of the drugs has led to the way for the entry of generics into the market. The extreme use of generic medicine can impede the demand for several branded drugs, therefore affecting the market.
This chapare hemorrhagic fever (CHHF) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chapare hemorrhagic fever (CHHF) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Chapare Hemorrhagic Fever (CHHF) Market Scope
The chapare hemorrhagic fever (CHHF) market is segmented on the basis of treatment, transmission, dosage, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Intravenous Therapy
- Pain Relievers
- Transfusions
- Management of hydration
- Others
Transmission
- Direct Contact
- Indirect Contact
Dosage
- Tablet
- Injection
- Others
Route of Administration
- Oral
- Intravenous
- Others
End-Users
- Hospitals
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Chapare Hemorrhagic Fever (CHHF) Market Regional Analysis/Insights
The chapare hemorrhagic fever (CHHF) market is analyzed and market size insights and trends are provided by treatment, transmission, dosage, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the chapare hemorrhagic fever (CHHF) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is the dominating region due to the rising occurrence of haemophilus influenzae infection and advanced healthcare facilities.
Asia-Pacific is considered the growing region because of the higher cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Chapare Hemorrhagic Fever (CHHF) Market Share Analysis
The chapare hemorrhagic fever (CHHF) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chapare hemorrhagic fever (CHHF) market
Key players operating in the chapare hemorrhagic fever (CHHF) market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
- Lupin (India)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Bausch Health Companies Inc. (Canada)
- WEX Pharmaceuticals Inc (Canada)
- Zynerba Pharmaceuticals, Inc (U.S.)
- Estrellas Life Sciences Private Limited (U.S.)
SKU-